A Novel Actin Binding Drug with In Vivo Efficacy. Academic Article uri icon

abstract

  • Occidiofungin is produced by the soil bacterium Burkolderia contaminans MS14 and is structurally similar or identical to the burkholdines, xylocandins, and cepacidines. This study identified the primary cellular target of occidiofungin, which was determined to be actin. The modification of occidiofungin with a functional alkyne group enabled affinity purification assays and localization studies in yeast. Occidiofungin has a subtle effect on actin dynamics that triggers apoptotic cell death. We demonstrate the highly specific localization of occidiofungin to cellular regions rich in actin in yeast and the binding of occidiofungin to purified actin in vitro Furthermore, a disruption of actin-mediated cellular processes, such as endocytosis, nuclear segregation, and hyphal formation, was observed. All of these processes require the formation of stable actin cables, which are disrupted following the addition of a subinhibitory concentration of occidiofungin. We were also able to demonstrate the effectiveness of occidiofungin in treating a vulvovaginal yeast infection in a murine model. The results of this study are important for the development of an efficacious novel class of actin binding drugs that may fill the existing gap in treatment options for fungal infections or different types of cancer.

published proceedings

  • Antimicrob Agents Chemother

altmetric score

  • 3.1

author list (cited authors)

  • Ravichandran, A., Geng, M., Hull, K. G., Li, J., Romo, D., Lu, S., ... Smith, L.

citation count

  • 23

complete list of authors

  • Ravichandran, Akshaya||Geng, Mengxin||Hull, Kenneth G||Li, Jing||Romo, Daniel||Lu, Shi-En||Albee, Aaron||Nutter, Christopher||Gordon, Donna M||Ghannoum, Mahmoud A||Lockless, Steve W||Smith, Leif

publication date

  • January 2019